Banking giant massively resets Jazz Pharma stock price target

Changes successful Wall Street terms targets usually get successful tiny increments. A fewer dollars up, a fewer dollars down, and sometimes a standing near untouched.

UBS skipped that publication with Jazz Pharmaceuticals (JAZZ).

On May 19, UBS expert Ashwani Verma upgraded Jazz Pharmaceuticals 2 notches, from neutral consecutive to buy, and lifted his terms people to $307 from $188. That is a 63% leap successful 1 move, and it sits good supra the anterior analyst statement of astir $242.

For a banal that has already climbed 39% twelvemonth to date and much than 100% over the past year, that benignant of reset is worthy a person look.

Why UBS raised its Jazz Pharma banal terms people now

Timing is what separates this telephone from a regular upgrade.

Verma's people reset lands conscionable up of an August 25 PDUFA day for zanidatamab, sold arsenic Ziihera, successful first-line HER2-positive gastroesophageal cancer. A PDUFA day is the deadline the FDA sets to determine whether to o.k. a drug, truthful it serves arsenic a hard catalyst investors tin people connected a calendar.

UBS expects that support to thrust a faster commercialized ramp than the marketplace assumes. The steadfast projects astir $3.1 cardinal successful highest Ziihera sales, helped by beardown Phase 3 HERIZON-GEA information and a projected 45% highest penetration successful its people market, Investing.com reports.

That faster ramp is the motor down the math.

How UBS justifies a $307 people connected Jazz stock

The $307 fig rests connected 2 levers moving together: higher maturation and a higher multiple.

UBS present forecasts 10% gross and 11% earnings-per-share compound yearly maturation from 2026 done 2030. Both tally up of the statement gait of astir 7% and 6%.

Related: UBS drops assertive Broadcom banal terms forecast

On that basis, Verma argues that JAZZ deserves a richer valuation, expanding his aggregate from 7 times to 10 times earnings.

In plain terms, helium thinks investors should wage much for each dollar of nett due to the fact that the maturation looks much sustainable.

What has to spell close for the Jazz Pharma bull case

• Ziihera clears its August 25 FDA review connected schedule.

• The oncology ramp tracks toward UBS's $3.1 cardinal highest estimate.

• Core franchises specified arsenic Xywav and Epidiolex support growing.

• The 7x-to-10x re-rating really sticks.

If the institution misses immoderate of these, the spread betwixt terms and people narrows fast.

What Jazz Pharma's caller 4th shows astir the setup

The upgrade did not travel retired of nowhere. Recent results gave UBS thing factual to physique on.

Jazz reported $1.07 cardinal successful first-quarter 2026 revenue, up 19% twelvemonth implicit year, with adjusted net of $6.34 per stock against a $4.66 consensus. The oncology portfolio grew 45%.